Skip to main content
PB

Percept Biosciences

This company develops AI agents that combine mechanistic reasoning with scalable automation to decode biological mechanisms and guide drug discovery experiments. They accelerate the translation of scientific insights to deliver transformative treatments more quickly to patients. Percept Biosciences provides actionable repurposing recommendations for patient advocacy groups and automates knowledge work for biotechs using their KoGent engine.

San Diego, United States450+ followers
Updated 2 months ago

Funding

Funding not disclosed

Funding rounds are not available yet.

Founders

Product

Problem

The drug development process frequently encounters failures, leading to valuable assets being shelved despite potential for repurposing. Identifying synergistic drug combinations across a broad spectrum of indications is a complex and time-consuming challenge.

Solution

Percept Biosciences leverages its proprietary Percept Engine to identify synergistic drug repurposing opportunities by integrating qualitative biological knowledge with quantitative data analysis. The platform systematically searches across all known indications to uncover optimal drug combinations, providing a data-driven strategy for clinical development and commercialization. This approach aims to resurrect shelved assets and accelerate the path to market for novel combination therapies. The Percept Engine's reasoning capabilities allow for a deeper understanding of molecular interactions and therapeutic potential.

Target Audience

Percept Biosciences targets pharmaceutical and biotechnology companies seeking to repurpose existing drug assets or discover novel combination therapies.

Features

  • AI-driven platform for identifying synergistic drug repurposing opportunities
  • Integration of qualitative biological knowledge with quantitative data analysis
  • Comprehensive indication assessment for molecule fit and repositioning
  • Proprietary algorithms for uncovering optimal drug combination strategies
  • Focus on accelerating clinical development and commercialization pathways for combination therapeutics
This profile is AI-generated and may contain inaccuracies.